arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Tyra Biosciences, Inc.

TYRA
$23.21 ▼ -2.34 (-9.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tyra Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -10.9%
FCF / Share $-0.47
Trailing P/E
Price / Book 3.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-39.30M
↓ -39.6%
FCF / Share Free cash flow per share
$-0.47
↑ +10.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
18
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters